An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients

Abstract

The resulting module with 29 questions, thus currently named EORTC QLQ-LC29, retained 12 of the 13 original items, supplemented with 17 items that primarily assess treatment side-effects of traditional and newer therapies.

Determinants of Cancer-specific Quality of Life in Veteran Lung Cancer Survivors Eligible for Long-Term Cure

“…fatigue). While there are ongoing efforts to create a more comprehensive lung cancer-specific instrument with a summary score 48 , it is not currently available. Thus, we used existing, symptom-specific questionnaires to incorporate these two important symptoms.…”

Effects of Curative-Intent Lung Cancer Therapy on Functional Exercise Capacity and Patient-Reported Outcomes

“…Despite the importance and frequency of abnormal symptoms of dyspnea and fatigue in lung cancer patients [42][43][44][45], these two symptoms are assessed by only one and three questions, respectively, in the 30-question EORTC-QLQ-C30, and only three and zero questions, respectively, in the 13-question EORTC-QLQ-LC13. While there are ongoing efforts to create a novel EORTC-QLQ-LC29 instrument with a summary score [46] to more accurately capture lung cancer-specific health, we used separate PRO questionnaires with more questions specifically on these two important symptoms (24 items in the UCSD SOBQ and 9 in the BFI). In this relatively small sample, we detected statistically and clinically meaningful increases/worsening in dyspnea and fatigue symptoms following treatment (as interpreted by their respective MCIDs: 5 points for the UCSD SOBQ [47] and 7 for the BFI [28]).…”

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

“…Assess the safety and determine the recommended phase II dose (RP2D) of each DDRi used in combination with radical RT for patients with LA-NSCLC. The RP2D will be the dose level at which it is estimated that 25% subjects will experience dose limiting toxicities (DLT) (see Table 2) during the 13.5 month period from the start of RT Secondary objectives include the description of: Safety profile (acute and late) using CTCAE v5.0 [41] and PROMs [42,43] Treatment adherence for each DDRi in combination with RT Overall radiotherapy treatment time Best overall response using RECIST 1.1 criteria [44] Progression free survival (PFS) using RECIST 1.1 criteria [44] Overall survival Exploratory objectives:…”

“…Response to treatment and PFS will be assessed by CT at 1 month following completion of RT and subsequently at 3, 6, 12, 18 and 24 months, according to RECIST 1.1 where possible [44]. Robust patient reported outcome measures will be captured with validated questionnaires (EORTC-QLQ C30, EORTC-QLQ-LC29), and additional items from the EORTC-QLQ Item Library to cover potential novel agent toxicities, before randomisation, immediately post-treatment and during follow-up [42,43].…”